Pre-Eclampsia And Growth Restriction: a Longitudinal Study
NCT ID: NCT02379832
Last Updated: 2019-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
76 participants
OBSERVATIONAL
2015-03-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
First-trimester Prediction of Preeclampsia
NCT02189148
Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn
NCT01648855
EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth Restriction
NCT01490489
Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening
NCT03067298
Prediction of Chronic Kidney Disease Following Pre-eclampsia: Diagnosis and Early Care
NCT05056701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Other studies show that some maternal factors, including the value of arterial pressure, BMI, maternal age, could contribute to screening for pre-eclampsia. Recent studies have also been interested in the maternal ophthalmic artery Doppler to try to predict preeclampsia even before the development of clinical symptoms.
Our hypothesis is that each of these biomarkers may be specific to a certain type of pre-eclampsia (early or late; with or without intra uterine growth restriction). We believe that actual definition of preeclampsia includes heterogenous causes and that better understanding of this pathology would help practicians to offer a more individualised treatment to their patients.
Objective: Our main goal is to characterize from a biophysical, biochemical, ultrasonographic and placental perspective the pathology of preeclampsia.
Method: This case-control study will recruit:
1. nulliparous women at 1st trimester of pregnancy. They will provide blood sample and U/S examination at 4 different times during pregnancy.
2. nulliparous women at diagnosis of preeclampsia.
Data that will be collected are:
maternal age maternal BMI maternal ethnicity maternal mean arterial pressure (at recruitment/diagnosis and delivery) gestational age at recruitment/diagnosis and at delivery maternal serum PAPP-A, PlGF, endoglin, sFlt-1 (at recruitment and delivery) cord blood PlGf, endoglin, sFlt-1 fetal crown-rump length at 1st trimester (at recruitment) fetal growth (during pregnancy) Uterine arteries Doppler Cord arteries Doppler Maternal Ophthalmic arteries Doppler Placental volume newborn birthweight
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cases
Nulliparous women recruited at diagnosis of preeclampsia No intervention, only observation of biochemical and ultrasonographic markers at recruitment and at delivery N= 45
No interventions assigned to this group
Control
Nulliparous women recruited at the beginning of pregnancy. No intervention, only observation of biochemical and ultrasonographic markers at recruitment (1st trimester), 3 other times during pregnancy (2nd and 3rd trimester) and at delivery N= 45
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Expect to deliver in recruiting center
* Control group: recruited between 11 - 13 6/7 weeks of gestation
* Case group: recruited at time of diagnosis of preeclampsia \> 20 weeks of gestation
Exclusion Criteria
* pregnant women \<18 years old at recruitment
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chaire Jeanne-et-Jean-Louis Lévesque en périnatalogie
UNKNOWN
Laval University
OTHER
CHU de Quebec-Universite Laval
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Emmanuel Bujold
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Emmanuel Bujold, MD, MSc
Role: PRINCIPAL_INVESTIGATOR
CHU de Québec
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU de Québec
Québec, , Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B14-07-2037
Identifier Type: OTHER
Identifier Source: secondary_id
B14-07-2037
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.